JPMorgan Chase & Co. Raises Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

JPMorgan Chase & Co. increased its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 8.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,610 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,670 shares during the quarter. JPMorgan Chase & Co.’s holdings in KalVista Pharmaceuticals were worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. State Street Corp raised its holdings in KalVista Pharmaceuticals by 68.1% during the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after buying an additional 515,179 shares during the last quarter. Vestal Point Capital LP increased its position in shares of KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after acquiring an additional 1,700,000 shares during the period. Barclays PLC increased its position in shares of KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after acquiring an additional 54,257 shares during the period. Readystate Asset Management LP bought a new position in shares of KalVista Pharmaceuticals during the third quarter valued at about $2,084,000. Finally, FMR LLC boosted its holdings in shares of KalVista Pharmaceuticals by 22.9% during the third quarter. FMR LLC now owns 66,423 shares of the specialty pharmaceutical company’s stock worth $769,000 after purchasing an additional 12,397 shares during the period.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 7,627 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the sale, the chief executive officer now owns 274,596 shares in the company, valued at $2,677,311. This represents a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the sale, the insider now directly owns 94,199 shares of the company’s stock, valued at $872,282.74. This trade represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,291 shares of company stock valued at $304,086. 10.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Bank of America assumed coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Finally, JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a report on Friday. They issued an “outperform” rating and a $19.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $23.80.

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $8.91 on Friday. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $16.88. The firm’s 50-day simple moving average is $8.83 and its two-hundred day simple moving average is $10.90. The stock has a market cap of $440.33 million, a PE ratio of -2.45 and a beta of 0.86.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. Equities research analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).